G S Sachin About This Tool The Libtayo (cemiplimab) Dosing & Scheduling Tool calculator is designed for healthcare professionals to quickly determine the administration schedule for patients based on the standard FDA-approved regimen. It simplifies planning by projecting future infusion dates from the last known dose, supporting adherence to the prescribed treatment timeline. Outputs After entering the required … Read more
About This Guidance This information supports the use of the Imfinzi (durvalumab) Dosing Calculator. It provides an overview of dosing regimens, administration details, and answers to frequently asked questions based on the approved prescribing information. This content is for informational purposes and should not replace clinical judgment or the full prescribing information. Calculator Outputs Explained … Read more
About this Content This information provides a supplementary guide to the Tecentriq (atezolizumab) Dosing Calculator. It outlines the tool’s functions, the data it presents, and key clinical considerations based on the Prescribing Information. Always use this tool in conjunction with independent clinical judgment. Outputs After entering the required patient and treatment parameters, the calculator provides … Read more
Clinical & Usage Information Supporting context for the Opdivo (nivolumab) dosing tool based on its underlying data and clinical practice principles. About This Tool The Opdivo (nivolumab) Dosing Calculator is designed for healthcare professionals to quickly determine patient-specific dosing based on approved regimens. It simplifies dose calculation for various oncologic indications by incorporating both flat-dose … Read more
About This Calculator The Keytruda (pembrolizumab) Dosing Calculator is a clinical support tool designed for healthcare professionals to determine appropriate dosing based on patient-specific factors. It simplifies calculations for various FDA-approved indications in both adult and pediatric populations, ensuring alignment with the official prescribing information. Outputs Explained Upon entering the required patient information, the calculator … Read more
About This Briumvi Calculator This clinical guide explains the key parameters and outputs of the Briumvi (ublituximab) Dosing Calculator. The information provided here is for educational purposes and is intended to supplement, not replace, the full prescribing information and professional clinical judgment. This guide covers dosing, administration, scheduling, and safety considerations based on the product … Read more
About This Calculator The Lemtrada (alemtuzumab) Dosing Calculator is a clinical support tool for healthcare professionals. It helps generate an administration schedule for the two initial treatment courses based on the standard dosing regimen outlined in the prescribing information. This tool is not a substitute for clinical judgment and all outputs must be verified. Outputs … Read more
About This Calculator The Ocrevus (ocrelizumab) Dosing Calculator is designed to assist healthcare professionals in determining the appropriate dosing schedule and infusion rates based on the official prescribing information. This tool simplifies the process of planning the initial and subsequent doses, including calculating key dates and providing standardized infusion rate tables for administration. It is … Read more
About This Tool This Tysabri (natalizumab) Dosing Calculator is designed to assist healthcare professionals in determining the next infusion date and stratifying patient risk for Progressive Multifocal Leukoencephalopathy (PML). It incorporates key risk factors outlined in the official prescribing information, including anti-JCV antibody status, treatment duration, and prior immunosuppressant use, to provide a comprehensive dosing … Read more
About This Tool This Crohn’s Disease Biologic Dosing Calculator is a clinical support tool designed for healthcare professionals to quickly reference standard dosing regimens for common biologic agents used in the treatment of adult Crohn’s disease. It covers induction and maintenance phases for Infliximab, Adalimumab, Certolizumab Pegol, Vedolizumab, Ustekinumab, and Risankizumab. The information provided is … Read more
